Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Flynn

Pediatric Endocrinology Boise, ID Medical Doctor

NPI 1447449574 CMS profile 246870

100 E Idaho St, Ste 200, Boise, ID 83712

Open in the dashboard

General payments

$107,309

191 records reported · program years 2019–2025

Research payments

$34,297

Paid to them · 6 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$493,299 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Daniel Flynn of Boise, ID is reported in the CMS Open Payments database as having received $107,309 across 191 general payments and $34,297 in research payments paid to them. Separately, studies naming them as principal investigator received $493,299 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,418 12
2025 Research $16 1
2024 General $23,418 20
2023 General $12,335 33
2023 Research $34,021 3
2022 General $34,883 56
2021 General $15,492 25
2020 General $2,711 7
2020 Research $255 1
2019 General $14,051 38
2019 Research $5 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Flynn
  • Pediatric Endocrinology median
  • Middle half of Pediatric Endocrinology
  • National median

In program year 2025, general payments to Daniel Flynn were reported at $4,418. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.

Show as a table
Year Daniel Flynn Pediatric Endocrinology median Middle half National median
2019 $14,051 $196 $68–$845 $163
2020 $2,711 $124 $37–$722 $114
2021 $15,492 $134 $35–$691 $132
2022 $34,883 $177 $47–$726 $149
2023 $12,335 $236 $75–$887 $160
2024 $23,418 $259 $91–$979 $164
2025 $4,418 $293 $106–$1,640 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $67,881 81 payments
  2. Novo Nordisk Inc $7,241 12 payments
  3. Medtronic MiniMed, Inc. $6,805 19 payments
  4. Ascendis Pharma, Inc. $6,460 9 payments
  5. Pfizer Inc. $5,349 8 payments
  6. Horizon Therapeutics plc $4,695 9 payments
  7. Sanofi-Aventis U.S. LLC $4,361 5 payments
  8. Eli Lilly and Company $1,416 5 payments
  9. Endo Pharmaceuticals Inc. $1,265 1 payment
  10. Tolmar, Inc. $674 2 payments
  11. Other $1,164 40 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for serving as faculty or as a speaker for a medical education program $35,388 12 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $23,731 8 payments
  3. Consulting Fee $22,075 11 payments
  4. Travel and Lodging $17,731 50 payments
  5. Food and Beverage $4,561 107 payments
  6. Honoraria $3,800 2 payments
  7. Education $24 1 payment
Products named General payments · program years 2019–2025
  1. FreeStyle Libre 3 $21,773 22 payments
  2. FREESTYLE LIBRE Diabetes Care $15,668 18 payments
  3. FreeStyle Libre Pro $14,725 10 payments
  4. FreeStyle Libre 2 $12,338 14 payments
  5. Norditropin $7,051 6 payments
  6. SKYTROFA $6,460 9 payments
  7. TEPEZZA $4,695 9 payments
  8. NGENLA $3,710 2 payments
  9. FreeStyle Libre Diabetes Care $3,361 16 payments
  10. HUMALOG $1,434 6 payments
  11. Other $4,521 59 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Sanofi US Services Inc. $34,021 3 payments
  2. Eli Lilly and Company $276 3 payments

Records

197 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Endocrinology in Idaho

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record